Last reviewed · How we verify
desvenlafaxine succinate sustained release tablets
desvenlafaxine succinate sustained release tablets is a Serotonin-norepinephrine reuptake inhibitor (SNRI) Small molecule drug developed by Pfizer. It is currently in Phase 3 development for Major depressive disorder, Generalized anxiety disorder. Also known as: DVS-233; Pristiq.
Desvenlafaxine succinate sustained release tablets are a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by increasing the levels of serotonin and norepinephrine in the brain.
Desvenlafaxine succinate sustained release tablets are a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by increasing the levels of serotonin and norepinephrine in the brain. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | desvenlafaxine succinate sustained release tablets |
|---|---|
| Also known as | DVS-233; Pristiq |
| Sponsor | Pfizer |
| Drug class | Serotonin-norepinephrine reuptake inhibitor (SNRI) |
| Target | Serotonin transporter, Norepinephrine transporter |
| Modality | Small molecule |
| Therapeutic area | Depression, Anxiety |
| Phase | Phase 3 |
Mechanism of action
By blocking the reuptake of serotonin and norepinephrine, desvenlafaxine succinate sustained release tablets increase the amount of these neurotransmitters available for use in the brain, which can help improve mood and reduce symptoms of depression and anxiety.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
- Insomnia
Key clinical trials
- Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder (NA)
- Study of Desvenlafaxine in Treating Major Depressive Disorder. (PHASE3)
- Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder (PHASE2)
- A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD (PHASE3)
- Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD) (PHASE3)
- A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD (PHASE3)
- A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD (PHASE3)
- A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- desvenlafaxine succinate sustained release tablets CI brief — competitive landscape report
- desvenlafaxine succinate sustained release tablets updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about desvenlafaxine succinate sustained release tablets
What is desvenlafaxine succinate sustained release tablets?
How does desvenlafaxine succinate sustained release tablets work?
What is desvenlafaxine succinate sustained release tablets used for?
Who makes desvenlafaxine succinate sustained release tablets?
Is desvenlafaxine succinate sustained release tablets also known as anything else?
What drug class is desvenlafaxine succinate sustained release tablets in?
What development phase is desvenlafaxine succinate sustained release tablets in?
What are the side effects of desvenlafaxine succinate sustained release tablets?
What does desvenlafaxine succinate sustained release tablets target?
Related
- Drug class: All Serotonin-norepinephrine reuptake inhibitor (SNRI) drugs
- Target: All drugs targeting Serotonin transporter, Norepinephrine transporter
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Depression, Anxiety
- Indication: Drugs for Major depressive disorder
- Indication: Drugs for Generalized anxiety disorder
- Also known as: DVS-233; Pristiq
- Compare: desvenlafaxine succinate sustained release tablets vs similar drugs
- Pricing: desvenlafaxine succinate sustained release tablets cost, discount & access